Viatris Inc (VTRS) - Total Assets

Latest as of March 2026: $36.83 Billion USD

Based on the latest financial reports, Viatris Inc (VTRS) holds total assets worth $36.83 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore debt repayment capacity of Viatris Inc to assess how comfortably operating cash covers total debt obligations.

Viatris Inc - Total Assets Trend (1985–2025)

This chart illustrates how Viatris Inc's total assets have evolved over time, based on quarterly financial data. See Viatris Inc book value and equity for net asset value and shareholders' equity analysis.

Viatris Inc - Asset Composition Analysis

Current Asset Composition (December 2025)

Viatris Inc's total assets of $36.83 Billion consist of 24.8% current assets and 75.2% non-current assets.

Asset Category Amount (USD) % of Total Assets
Cash & Equivalents $0.00 3.6%
Accounts Receivable $3.35 Billion 9.0%
Inventory $4.00 Billion 10.8%
Property, Plant & Equipment $0.00 0.0%
Intangible Assets $15.10 Billion 40.6%
Goodwill $6.75 Billion 18.2%

Asset Composition Trend (1985–2025)

This chart illustrates how Viatris Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see VTRS company net worth.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Viatris Inc's current assets represent 24.8% of total assets in 2025, a decrease from 79.5% in 1985.
  • Cash Position: Cash and equivalents constituted 3.6% of total assets in 2025, down from 26.8% in 1985.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 58.0% of total assets, an increase from 0.0% in 1985.
  • Asset Diversification: The largest asset category is intangible assets at 40.6% of total assets.

Viatris Inc Competitors by Total Assets

Key competitors of Viatris Inc based on total assets are shown below.

Company Country Total Assets
Takeda Pharmaceutical Company Limited
F:TKDA
Germany €15.41 Trillion
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131
China CN¥6.49 Billion
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
China CN¥4.44 Billion
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
China CN¥7.28 Billion
Celltrion Pharm Inc
KQ:068760
Korea ₩745.80 Billion
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
China CN¥1.54 Billion
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567
China CN¥11.80 Billion
Zhejiang Anglikang Pharmaceutical Co Ltd Class A
SHE:002940
China CN¥3.12 Billion

Viatris Inc - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 1.60 1.68 1.16
Quick Ratio 1.03 0.97 0.72
Cash Ratio 0.00 0.00 0.00
Working Capital $4.11 Billion $3.90 Billion $1.62 Billion

Viatris Inc - Advanced Valuation Insights

This section examines the relationship between Viatris Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 1.30
Latest Market Cap to Assets Ratio 0.51
Asset Growth Rate (YoY) -10.4%
Total Assets $37.19 Billion
Market Capitalization $18.99 Billion USD

Valuation Analysis

Below Book Valuation: The market values Viatris Inc's assets below their book value (0.51x), which may indicate investor concerns about asset quality or future growth.

Significant Asset Reduction: Viatris Inc's assets decreased by 10.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for Viatris Inc (1985–2025)

The table below shows the annual total assets of Viatris Inc from 1985 to 2025.

Year Total Assets Change
2025-12-31 $37.19 Billion -10.38%
2024-12-31 $41.50 Billion -12.97%
2023-12-31 $47.69 Billion -4.67%
2022-12-31 $50.02 Billion -8.79%
2021-12-31 $54.84 Billion -10.90%
2020-12-31 $61.55 Billion +96.93%
2019-12-31 $31.26 Billion -4.52%
2018-12-31 $32.73 Billion -8.58%
2017-12-31 $35.81 Billion +3.11%
2016-12-31 $34.73 Billion +55.95%
2015-12-31 $22.27 Billion +40.75%
2014-12-31 $15.82 Billion +3.44%
2013-12-31 $15.29 Billion +28.18%
2012-12-31 $11.93 Billion +2.88%
2011-12-31 $11.60 Billion +0.53%
2010-12-31 $11.54 Billion +6.81%
2009-12-31 $10.80 Billion +3.93%
2008-12-31 $10.39 Billion -8.45%
2007-12-31 $11.35 Billion +166.89%
2006-12-31 $4.25 Billion +127.42%
2005-12-31 $1.87 Billion -12.42%
2004-12-31 $2.14 Billion +13.29%
2003-12-31 $1.89 Billion +8.01%
2002-12-31 $1.75 Billion +7.95%
2001-12-31 $1.62 Billion +10.28%
2000-12-31 $1.47 Billion +9.30%
1999-12-31 $1.34 Billion +11.15%
1998-12-31 $1.21 Billion +42.33%
1997-12-31 $847.80 Million +9.03%
1996-12-31 $777.60 Million +12.37%
1995-12-31 $692.00 Million +26.69%
1994-12-31 $546.20 Million +35.43%
1993-12-31 $403.30 Million +14.87%
1992-12-31 $351.10 Million +54.87%
1991-12-31 $226.70 Million +33.67%
1990-12-31 $169.60 Million +23.35%
1989-12-31 $137.50 Million +22.01%
1988-12-31 $112.70 Million +3.58%
1987-12-31 $108.80 Million +35.49%
1986-12-31 $80.30 Million +43.39%
1985-12-31 $56.00 Million --

About Viatris Inc

NASDAQ:VTRS USA Drug Manufacturers - Specialty & Generic
Market Cap
$20.45 Billion
Market Cap Rank
#1331 Global
#544 in USA
Share Price
$17.56
Change (1 day)
-1.13%
52-Week Range
$8.75 - $17.86
All Time High
$47.92
About

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and … Read more